InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

Price
Live  
Infographic
Infographics
Overview
Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.
How to explain to a 10 year old kid about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgY2 9tcGFueSB0 aGF0IGZvY3 VzZXMgb24g bWFraW5nIG 1lZGljaW5l cywgZXNwZW NpYWxseSBm b3Igc2VyaW 91cyBkaXNl YXNlcyBsaW tlIEhJViwg bGl2ZXIgcH JvYmxlbXMs IGFuZCBzb2 1lIHR5cGVz IG9mIGNhbm Nlci4gSW1h Z2luZSBHaW xlYWQgYXMg YSBzdXBlcm hlcm8gdGhh dCBjcmVhdG VzIHNwZWNp YWwgcG90aW 9ucyB0byBo ZWxwIHBlb3 BsZSBmZWVs IGJldHRlci BhbmQgbGl2 ZSBoZWFsdG hpZXIgbGl2 ZXMuPGJyPl RoZSB3YXkg R2lsZWFkIG 1ha2VzIG1v bmV5IGlzIG J5IGNyZWF0 aW5nIHRoZX NlIG1lZGlj aW5lcyBhbm QgdGhlbiBz ZWxsaW5nIH RoZW0gdG8g aG9zcGl0YW xzIGFuZCBw aGFybWFjaW VzLiBEb2N0 b3JzIHVzZS B0aGVzZSBt ZWRpY2luZX MgdG8gaGVs cCBwYXRpZW 50cyBnZXQg YmV0dGVyLC BhbmQgdGhl IGhvc3BpdG FscyBwYXkg R2lsZWFkIG ZvciB0aGUg ZHJ1Z3MuIF NvbWV0aW1l cywgdGhleS BhbHNvIHdv cmsgd2l0aC BiaWcgcmVz ZWFyY2ggZ3 JvdXBzIHRv IGRpc2Nvdm VyIG5ldyBt ZWRpY2luZX MsIGFuZCB0 aGlzIGNhbi BicmluZyBp biBldmVuIG 1vcmUgbW9u ZXkuPGJyPk dpbGVhZCBp cyBzdWNjZX NzZnVsIGZv ciBhIGZldy ByZWFzb25z LiBGaXJzdC wgdGhleSBp bnZlc3QgYS Bsb3Qgb2Yg dGltZSBhbm QgbW9uZXkg aW50byByZX NlYXJjaCB0 byBmaW5kIG 5ldyB0cmVh dG1lbnRzLi BUaGlzIG1l YW5zIHRoZX nigJlyZSBh bHdheXMgdH J5aW5nIHRv IGNyZWF0ZS BiZXR0ZXIg YW5kIG1vcm UgZWZmZWN0 aXZlIG1lZG ljaW5lcy4g U2Vjb25kLC B0aGV5IGhh dmUgc3Ryb2 5nIHBhdGVu dHMsIHdoaW NoIGFyZSBs aWtlIHByb3 RlY3RpdmUg c2hpZWxkcy B0aGF0IGtl ZXAgb3RoZX IgY29tcGFu aWVzIGZyb2 0gY29weWlu ZyB0aGVpci BkcnVncyBm b3IgYSBjZX J0YWluIG51 bWJlciBvZi B5ZWFycy4g VGhpcyBoZW xwcyB0aGVt IHNlbGwgdG hlaXIgbWVk aWNpbmVzIH dpdGhvdXQg bXVjaCBjb2 1wZXRpdGlv bi4gTGFzdG x5LCBhcyBt b3JlIHBlb3 BsZSBhcm91 bmQgdGhlIH dvcmxkIG5l ZWQgaGVhbH RoY2FyZSBh bmQgYmV0dG VyIHRyZWF0 bWVudHMsIE dpbGVhZCBp cyB3ZWxsLX Bvc2l0aW9u ZWQgdG8gaG VscCB0aGVt LCB3aGljaC BtZWFucyB0 aGV5IHdpbG wgbGlrZWx5 IGNvbnRpbn VlIHRvIGJl IHN1Y2Nlc3 NmdWwgaW4g dGhlIGZ1dH VyZS48YnI+ SW4gc3VtbW FyeSwgR2ls ZWFkIFNjaW VuY2VzIGlz IGdvb2QgYX QgbWFraW5n IG1lZGljaW 5lcyB0aGF0 IGhlbHAgZm lnaHQgYmln IGlsbG5lc3 NlcywgdGhl eSBrbm93IG hvdyB0byBt YWtlIG1vbm V5IGJ5IHNl bGxpbmcgdG hvc2UgbWVk aWNpbmVzLC BhbmQgdGhl eSBoYXZlIH RoZSBza2ls bHMgYW5kIH BsYW5zIHRv IHJlbWFpbi BhIHN0cm9u ZyBwbGF5ZX IgaW4gdGhl IGhlYWx0aG NhcmUgaW5k dXN0cnkgZm 9yIHllYXJz IHRvIGNvbW UuPGJyPg==
What is special about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=
What the company's business model?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==
Is AI a threat?
AI does pose potential threats to Gilead Sciences, primarily through substitution, disintermediation, and margin pressure, but the extent of these threats is influenced by various factors specific to the pharmaceutical industry.
1. Substitution: AI technologies are advancing rapidly, particularly in drug discovery and development. Machine learning algorithms can analyze vast datasets to identify new drug candidates, which could lead to the development of competing therapies that may replace existing Gilead products. Additionally, AI-driven personalized medicine approaches could tailor treatments more effectively than Gilead’s current offerings, potentially eroding market share if Gilead does not adapt.
2. Disintermediation: AI could change the traditional pharmaceutical supply chain and patient care models. For instance, AI-enabled platforms could facilitate direct connections between drug developers and patients, bypassing traditional distribution channels. This shift could challenge Gilead’s ability to reach customers effectively, reducing the role of established intermediaries like pharmacies and distributors.
3. Margin Pressure: The implementation of AI in healthcare often aims to increase efficiency and reduce costs. If competitors leverage AI to streamline their operations or reduce the costs associated with R&D, they might be able to offer products at lower prices or with higher margins. Gilead may face pressure to lower its own prices or invest in new AI technologies to maintain a competitive position, which can affect profit margins.
Overall, while AI presents various risks to Gilead Sciences, the company’s response, including its investment in AI technologies and its ability to innovate, will play a crucial role in determining the actual impact of these threats on its products, services, and competitive positioning.
Sensitivity to interest rates
Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.
Resilience to the future changes
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

T25lIHJlYW xpc3RpYyBz Y2VuYXJpby B0aGF0IGNv dWxkIHBlcm 1hbmVudGx5 IGltcGFpci BHaWxlYWQg U2NpZW5jZX PigJkgZWNv bm9taWNzIG 92ZXIgdGhl IG5leHQgM+ KAkzUgeWVh cnMgaXMgdG hlIGxvc3Mg b2YgZXhjbH VzaXZpdHkg YW5kIGNvbX BldGl0aXZl IG1hcmtldC BwcmVzc3Vy ZXMgaW4gaX RzIGNvcmUg dGhlcmFwZX V0aWMgYXJl YXMsIHBhcn RpY3VsYXJs eSBpbiB0aG UgSElWIGFu ZCBoZXBhdG l0aXMgQyBz ZWdtZW50cy 4gPGJyPkFz IHBhdGVudC Bwcm90ZWN0 aW9ucyBvbi BrZXkgZHJ1 Z3MgbGlrZS BCaWt0YXJ2 eSAoZm9yIE hJVikgYW5k IEhhcnZvbm kgb3IgRXBj bHVzYSAoZm 9yIGhlcGF0 aXRpcyBDKS BleHBpcmUs IEdpbGVhZC BtYXkgZmFj ZSBzaWduaW ZpY2FudCBj b21wZXRpdG lvbiBmcm9t IGdlbmVyaW MgbWFudWZh Y3R1cmVycy BhbmQgYmlv c2ltaWxhcn MuIFRoaXMg ZXJvc2lvbi BvZiBtYXJr ZXQgZXhjbH VzaXZpdHkg Y2FuIGxlYW QgdG8gaW50 ZW5zZSBwcm ljZSBjb21w ZXRpdGlvbi wgc2lnbmlm aWNhbnRseS BpbXBhY3Rp bmcgdGhlIG NvbXBhbnni gJlzIHJldm VudWUgc3Ry ZWFtcy48Yn I+SW4gdGhp cyBzY2VuYX JpbywgR2ls ZWFk4oCZcy BtYXJnaW5z IHdvdWxkIG xpa2VseSBk ZWNyZWFzZS BzdWJzdGFu dGlhbGx5Li BXaXRoIHRo ZSBpbnRyb2 R1Y3Rpb24g b2YgbG93ZX ItY29zdCBh bHRlcm5hdG l2ZXMsIHRo ZSBjb21wYW 55IHdvdWxk IGVpdGhlci BoYXZlIHRv IGxvd2VyIG l0cyBwcmlj ZXMgdG8gcm VtYWluIGNv bXBldGl0aX ZlIG9yIGxv c2UgbWFya2 V0IHNoYXJl LCBsZWFkaW 5nIHRvIHJl ZHVjZWQgZ3 Jvc3MgbWFy Z2lucy4gSW YgZ3Jvc3Mg bWFyZ2lucy BmYWxsIGZy b20gdGhlaX IgY3VycmVu dCBsZXZlbH MgKG9mdGVu IGluIHRoZS ByYW5nZSBv ZiA4MCUgZm 9yIGNlcnRh aW4gcHJvZH VjdHMpIHRv LCBzYXksIG Fyb3VuZCA1 MC02MCUsIG 5ldCBtYXJn aW5zIHdvdW xkIGFsc28g YmUgYWR2ZX JzZWx5IGFm ZmVjdGVkLC BpbXBhY3Rp bmcgcHJvZm l0IGxldmVs cy48YnI+Q2 FzaCBmbG93 IHdvdWxkIG JlIGEgc2ln bmlmaWNhbn QgY29uY2Vy biB1bmRlci B0aGlzIHNj ZW5hcmlvLi BBcyByZXZl bnVlcyBkZW NsaW5lIGR1 ZSB0byBjb2 1wZXRpdGl2 ZSBwcmVzc3 VyZXMgYW5k IHByaWNpbm cgc3RyYXRl Z2llcywgZn JlZSBjYXNo IGZsb3cgY2 91bGQgZGlt aW5pc2ggY2 9uc2lkZXJh Ymx5LiBJZi BHaWxlYWQg dHlwaWNhbG x5IGdlbmVy YXRlcyBiaW xsaW9ucyBp biBmcmVlIG Nhc2ggZmxv dywgYSAzMC 01MCUgcmVk dWN0aW9uIG R1ZSB0byBs b3dlciByZX ZlbnVlcyBh bmQgbWFyZ2 lucyBjb3Vs ZCBsZWFkIH RvIGNoYWxs ZW5nZXMgaW 4gZnVuZGlu ZyByZXNlYX JjaCBhbmQg ZGV2ZWxvcG 1lbnQsIGRp dmlkZW5kcy wgb3Igc2hh cmUgYnV5Ym Fja3MuIFRo ZSBjb21wYW 55IG1pZ2h0 IGFsc28gaG F2ZSB0byBy ZWNvbnNpZG VyIGl0cyBp bnZlc3RtZW 50IHN0cmF0 ZWdpZXMgb3 IgZXhwbG9y ZSBjb3N0LW N1dHRpbmcg bWVhc3VyZX MuPGJyPk9u IHRoZSBiYW xhbmNlIHNo ZWV0LCBHaW xlYWQgY291 bGQgc2VlIG luY3JlYXNl ZCBwcmVzc3 VyZSBpZiBy ZXZlbnVlcy BmYWxsIHNp Z25pZmljYW 50bHkuIFdp dGggZGVjbG luaW5nIGNh c2ggZmxvdy wgdGhlIGNv bXBhbnnigJ lzIGFiaWxp dHkgdG8gbW FpbnRhaW4g aXRzIGNhc2 ggcmVzZXJ2 ZXMgbWF5IG JlIGhhbXBl cmVkLCBsZW FkaW5nIHRv IGEgZGVjcm Vhc2UgaW4g aXRzIGxpcX VpZGl0eSBw b3NpdGlvbi 4gSWYgR2ls ZWFkIGhhcy BleGlzdGlu ZyBkZWJ0IC h3aGljaCBp dCBkb2VzKS wgdGhlcmUg Y291bGQgYm UgcmlzaW5n IGNvbmNlcm 5zIGFib3V0 IGRlYnQgc2 VydmljZSBj b3ZlcmFnZS ByYXRpb3Mu IFRoZSBjb2 1wYW554oCZ cyBsZXZlcm FnZSBjb3Vs ZCBpbmNyZW FzZSBpZiBp dCB0b29rIG 9uIGFkZGl0 aW9uYWwgZG VidCB0byBz dXBwb3J0IG 9wZXJhdGlv bnMgb3IgaW 52ZXN0IGlu IG5ldyBSJm FtcDtELCB0 cmFuc2xhdG luZyB0byBh IGxlc3MgZm F2b3JhYmxl IGZpbmFuY2 lhbCBwb3Np dGlvbi48Yn I+SW4gc3Vt bWFyeSwgaW YgR2lsZWFk IFNjaWVuY2 VzIHdlcmUg dG8gZmFjZS BzaWduaWZp Y2FudCBwYX RlbnQgZXhw aXJhdGlvbn MgYW5kIGlu Y3JlYXNlZC BtYXJrZXQg Y29tcGV0aX Rpb24sIHRo ZSByZXN1bH RpbmcgcHJl c3N1cmUgb2 4gaXRzIHJl dmVudWUgc3 RyZWFtcywg bWFyZ2lucy wgYW5kIGNh c2ggZmxvdy Bjb3VsZCBs ZWFkIHRvIG Egd2Vha2Vu ZWQgYmFsYW 5jZSBzaGVl dCwgaW1wYW N0aW5nIGl0 cyBsb25nLX Rlcm0gdmlh YmlsaXR5IG FuZCBncm93 dGggcHJvc3 BlY3RzLjxi cj4=
Interesting facts about the company
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 NTAgd2lkdG g9NTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg4p yN77iPIFNp Z24gdXAgdG 8gZ2V0IDxp PiJUaGUgQ2 hlY2tsaXN0 IFZhbHVlIE ludmVzdG9y IOKAlCBBIF NtYXJ0ZXIg V2F5IHRvIF BpY2sgU3Rv Y2tzIjwvaT 4gZm9yIGZy ZWUKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIFIy bHNaV0ZrSU YgTmphV1Z1 WTJWeiBMQ0 JKYm1NdUlH IGx6SUdFZ1 ltbHYgY0do aGNtMWhZMi BWMWRHbGpZ V3dnIFkyOX RjR0Z1ZVMg QmlZWE5sWk NCcCBiaUJH YjNOMFpYIE lnUTJsMGVT d2cgUTJGc2 FXWnZjbSA1 cFlTd2dhMj V2IGQyNGda bTl5SUcgbD BjeUJtYjJO MSBjeUJ2Ym lCaGJuIFJw ZG1seVlXd2 cgWkhKMVoz TXNJSCBCaG NuUnBZM1Zz IFlYSnNlU0 IwYUcgOXpa U0IxYzJWay BJSFJ2SUhS eVpXIEYwSU VoSlZpd2cg YUdWd1lYUn BkRyBseklF SXNJR2hsIG NHRjBhWFJw Y3kgQkRMQ0 JoYm1RZyBh VzVtYkhWbG JuIHBoTGlC SVpYSmwgSU dGeVpTQnpi MiAxbElHbH VkR1Z5IFpY TjBhVzVuSU cgWmhZM1J6 SUdGaSBiM1 YwSUhSb1pT IEJqYjIxd1 lXNTUgT2p4 aWNqNHhMaS BBOGMzUnli MjVuIFBrWn ZkVzVrYVcg NW5QQzl6ZE hKdiBibWMr T2lCSGFXIH hsWVdRZ1Uy TnAgWlc1al pYTWdkMiBG eklHWnZkVz VrIFpXUWdh VzRnTVQgaz ROeUJpZVNC RSBjaTRnVF dsamFHIEZs YkNCTUxpQl MgYVc5eVpH RnVMaSBCVW FHVWdZMjl0 IGNHRnVlZU tBbVggTWdi bUZ0WlN3Zy BSMmxzWldG a0xDIEJwY3 lCa1pYSnAg ZG1Wa0lHWn liMiAwZ1lT QmlhV0pzIG FXTmhiQ0J3 YkcgRmpaU0 JyYm05MyBi aUJtYjNJZ2 FHIFZoYkds dVp5NDggWW 5JK01pNGdQ SCBOMGNtOX VaejVJIFNW WWdUV1ZrYV cgTmhkR2x2 Ym5NOCBMM0 4wY205dVp6 IDQ2SUVkcG JHVmggWkNC cGN5QmhJRy B4bFlXUmxj aUJwIGJpQm taWFpsYkcg OXdhVzVuSU dGdSBkR2x5 WlhSeWIzIF pwY21Gc0lI Um8gWlhKaG NHbGxjeSBC bWIzSWdTRW xXIExpQlVh R1VnWTIgOX RjR0Z1ZWVL QSBtWE1nWk hKMVozIE1z SUhOMVkyZ2 cgWVhNZ1ZI SjFkbSBGa1 lTQmhibVFn IFFtbHJkR0 Z5ZG4ga3NJ R2hoZG1VZy BjR3hoZVdW a0lHIEVnYz JsbmJtbG0g YVdOaGJuUW djbSA5c1pT QnBiaUJwIG JYQnliM1pw Ym0gY2dkR2 hsSUd4cCBk bVZ6SUc5bU lIIEJsYjNC c1pTQnMgYV hacGJtY2dk MiBsMGFDQk lTVll1IFBH SnlQak11SU QgeHpkSEp2 Ym1jKyBTR1 Z3WVhScGRH IGx6SUVNZ1 ZISmwgWVhS dFpXNTBQQy A5emRISnZi bWMrIE9pQk hhV3hsWVcg UWdaR1YyWl d4diBjR1Zr SUZOdmRtIE ZzWkdrZ1lX NWsgSUVoaG NuWnZibSBr c0lHZHliM1 Z1IFpHSnla V0ZyYVcgNW 5JSFJ5WldG MCBiV1Z1ZE hNZ1ptIDl5 SUdobGNHRj AgYVhScGN5 QkRMaSBCVW FHVnpaU0Jr IGNuVm5jeU JvWVggWmxJ SEpsZG05cy BkWFJwYjI1 cGVtIFZrSU hSb1pTQjAg Y21WaGRHMW xibiBRZ2JH RnVaSE5qIF lYQmxMQ0J2 Wm0gWmxjbW x1WnlCbyBh V2RvSUdOMW NtIFVnY21G MFpYTWcgWV c1a0lISmxi RyBGMGFYWm xiSGtnIGMy aHZjblFnZE ggSmxZWFJ0 Wlc1MCBJR1 IxY21GMGFX IDl1Y3k0OF luSSsgTkM0 Z1BITjBjbS A5dVp6NURU MVpKIFJDMH hPU0JTWlgg TndiMjV6Wl R3diBjM1J5 YjI1blBqIG 9nU1c0Z01q QXkgTUN3Z1 IybHNaVyBG a0lISmxjSF Z5IGNHOXpa V1FnYVggUn pJR0Z1ZEds MiBhWEpoYk NCa2NuIFZu SUhKbGJXUm wgYzJsMmFY SXNJRyA5eW FXZHBibUZz IGJIa2daR1 YyWlcgeHZj R1ZrSUdadi BjaUJGWW05 c1lTIHdnZE c4Z2RISmwg WVhRZ1EwOV dTVSBRdE1U a3VJRkpsIG JXUmxjMmwy YVggSWdjbV ZqWldsMiBa V1FnWlcxbG NtIGRsYm1O NUlIVnogWl NCaGRYUm9i MyBKcGVtRj BhVzl1IElH WnliMjBnZE cgaGxJRVpF UVNCaCBjeU J2Ym1VZ2Iy IFlnZEdobE lHWnAgY25O MElHRnVkRy BsMmFYSmhi Q0IwIGNtVm hkRzFsYm4g UnpJR1p2Y2 lCRCBUMVpK UkMweE9TID Q4WW5JK05T NGcgUEhOMG NtOXVaeiA1 U1pYTmxZWE pqIGFDQmhi bVFnUkcgVj JaV3h2Y0cx bCBiblE4TD NOMGNtIDl1 Wno0NklFZH AgYkdWaFpD QnBibiBabG MzUnpJR2hs IFlYWnBiSG tnYVcgNGdj bVZ6WldGeS BZMmdnWVc1 a0lHIFJsZG 1Wc2IzQnQg Wlc1MExDQn ZabiBSbGJp QnpjR1Z1IF pHbHVaeUJo SUggTnBaMj VwWm1saiBZ VzUwSUhCdm NuIFJwYjI0 Z2IyWWcgYV hSeklISmxk bSBWdWRXVn pJSFJ2IElH UnBjMk52ZG 0gVnlJR0Z1 WkNCayBaWF psYkc5d0lH IDVsZHlCMG FHVnkgWVhC bGRYUnBZMy BNZ1lXTnli M056IElIWm hjbWx2ZFgg TWdaR2x6Wl dGeiBaU0Jo Y21WaGN5IH dnYVc1amJI VmsgYVc1bk lHOXVZMiA5 c2IyZDVJR0 Z1IFpDQnBi bVpzWVcgMX RZWFJ2Y25r ZyBaR2x6Wl dGelpYIE11 UEdKeVBqWX UgSUR4emRI SnZibSBjK1 FXTnhkV2x6 IGFYUnBiMj V6UEMgOXpk SEp2Ym1jKy BPaUJVYUdV Z1kyIDl0Y0 dGdWVTQm8g WVhNZ1pYaH dZVyA1a1pX UWdhWFJ6IE lIQnZjblJt YjIgeHBieU IwYUhKdiBk V2RvSUhOMG NtIEYwWldk cFl5QmggWT NGMWFYTnBk RyBsdmJuTX NJR2x1IFky eDFaR2x1Wn kgQmlkWGxw Ym1jZyBTMm wwWlNCUWFH IEZ5YldFc0 lIZG8gYVdO b0lHRnNiRy A5M1pXUWdS MmxzIFpXRm tJSFJ2SUcg VnVkR1Z5SU hSbyBaU0Jt YVdWc1pDIE J2WmlCalpX eHMgSUhSb1 pYSmhjSCBr Z1ptOXlJR0 5oIGJtTmxj aUIwY20gVm hkRzFsYm5R dSBQR0p5UG pjdUlEIHh6 ZEhKdmJtYy sgUjJ4dllt RnNJRiBKbF lXTm9QQzl6 IGRISnZibW MrT2kgQkhh V3hsWVdRZy BiM0JsY21G MFpYIE1nYV c0Z2IzWmwg Y2lBek5TQm piMyBWdWRI SnBaWE1zIE lIZHBkR2dn WVMgQnphV2 R1YVdacCBZ MkZ1ZENCd2 NtIFZ6Wlc1 alpTQnAgYm lCRmRYSnZj RyBVZ1lXNW tJRUZ6IGFX RXVJRlJvWl MgQmpiMjF3 WVc1NSBJR2 x6SUdOdmJX IDFwZEhSbF pDQjAgYnlC dFlXdHBibS BjZ2FYUnpJ RzFsIFpHbG pZWFJwYjIg NXpJR0ZqWT JWeiBjMmxp YkdVZ2FXID RnYkc5M0xT QmggYm1RZ2 JXbGtaRyB4 bExXbHVZMj l0IFpTQmpi M1Z1ZEggSn BaWE1nZEdo eSBiM1ZuYU NCMllYIEpw YjNWeklIQn kgYVdOcGJt Y2djMyBSeV lYUmxaMmxs IGN5QmhibV FnY0cgRnlk RzVsY25Oby BhWEJ6TGp4 aWNqIDQ0TG lBOGMzUnkg YjI1blBrTn ZjbiBCdmNt RjBaU0JUIG IyTnBZV3dn VW0gVnpjRz l1YzJsaSBh V3hwZEhrOE wzIE4wY205 dVp6NDYgSU VkcGJHVmha QyBCcGN5Qn Biblp2IGJI WmxaQ0JwYm kgQnVkVzFs Y205MSBjeU JwYm1sMGFX IEYwYVhabG N5QmggYVcx bFpDQmhkQy BCcGJYQnli M1pwIGJtY2 daMnh2WW0g RnNJR2hsWV d4MCBhQ3dn YzNWamFDIE JoY3lCemRY QncgYjNKMG FXNW5JSCBK bGMyVmhjbU 5vIElHOXVJ RWhKVmkgOU JTVVJUSUhC eSBaWFpsYm 5ScGIyIDRn WVc1a0lIUn kgWldGMGJX VnVkQyBCcG JpQjFibVJs IGNpMXlaWE 52ZFggSmpa V1FnWTI5MS BiblJ5YVdW ekxqIHhpY2 o0NUxpQTgg YzNSeWIyNW 5QayBGdWJu VmhiQ0JTIF pYWmxiblZs UEMgOXpkSE p2Ym1jKyBP aUJIYVd4bF lXIFFnYVhN Z2IyNWwgSU c5bUlIUm9a UyBCc1lYSm 5aWE4wIElH SnBiM1JsWT IgaHViMnh2 WjNrZyBZMj l0Y0dGdWFX IFZ6SUdKNU lISmwgZG1W dWRXVXNJRy BOdmJuTnBj M1JsIGJuUn NlU0J5Wlgg QnZjblJwYm 1jZyBZbWxz YkdsdmJuIE 1nYVc0Z2NI SnYgWm1sMG N5d2daSCBK cGRtVnVJR3 hoIGNtZGxi SGtnWW4ga2 dhWFJ6SUds dSBibTkyWV hScGRtIFVn ZEdobGNtRn cgYVdWekxq eGljaiA0eE 1DNGdQSE4w IGNtOXVaej VYYjMgSnJj R3hoWTJVZy BRM1ZzZEhW eVpUIHd2Yz NSeWIyNW4g UGpvZ1ZHaG xJRyBOdmJY QmhibmtnIF pXMXdhR0Z6 YVggcGxjeU JoSUdOdiBi R3hoWW05eV lYIFJwZG1V Z1lXNWsgSU dsdVkyeDFj MiBsMlpTQj NiM0pyIGNH eGhZMlVnWT MgVnNkSFZ5 WlNCaCBibV FnYUdGeklH IEpsWlc0Z2 NtVmogYjJk dWFYcGxaQy BCbWIzSWdh WFJ6IElHVn RjR3h2ZVcg VmxMV1p5YV dWdSBaR3g1 SUhCdmJHIG xqYVdWeklH RnUgWkNCd2 NtRmpkRyBs alpYTXVQR0 p5IFBsUm9a WE5sSUcgWm hZM1J6SUdo cCBaMmhzYV dkb2RDIEJI YVd4bFlXUW cgVTJOcFpX NWpaWCBQaW dKa2djMmxu IGJtbG1hV0 5oYm4gUWdZ Mjl1ZEhKcC BZblYwYVc5 dWN5IEIwYn lCdFpXUnAg WTJsdVpTd2 djRyBGeWRH bGpkV3hoIG NteDVJR2x1 SUggUm9aU0 JtYVdWcyBa SE1nYjJZZ2 FXIDVtWldO MGFXOTEgY3 lCa2FYTmxZ WCBObGN5Qm hibVFnIGIy NWpiMnh2Wj Mga3VQR0p5 UGc9PQogIC AgICAgIDwv c3Bhbj4KIC AgICAgICAK ICAgICAgIC A=
See Company Q&A
Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal